Hyperthermic isolated limb perfusion (HILP) with various chemotherapeutic agents has been used for the local treatment of high-grade soft tissue sarcomas (STS) of the extremities, but in most cases with a disappointing result. Most regimens should certainly not be considered superior to surgery plus radiotherapy. Although the majority of extremity STS can be resected locally, some have a very large size and are in close proximity to bones, nerves or blood vessels. In these cases, amputation is the only means of resecting the tumour. A new combination of drugs used in the set-up of HILP with turnout necrosis factor-α and melphalan has emerged as a very promising option for the limb-saying management of locally advanced STS. In recent studies, complete response rates of approximately 30% and partial remission rates of 50% have been achieved, while the overall limb- salvage rate is more than 80%.

, ,
doi.org/10.1016/S0167-8140(98)00040-1, hdl.handle.net/1765/68639
Radiotherapy & Oncology
Department of Surgery

Koops, H. S., Eggermont, A., Liénard, D., Kroon, B., Hoekstra, H., van Geel, A., … Lejeune, F. (1998). Hyperthermic isolated limb perfusion with tumour necrosis factor and melphalan as treatment of locally advanced or recurrent soft tissue sarcomas of the extremities. Radiotherapy & Oncology (Vol. 48, pp. 1–4). doi:10.1016/S0167-8140(98)00040-1